Health News

At the Medicap Pharmacy® stores, we are dedicated to providing products and services to care for your family’s wellness. One of those services is health news you can trust. Use the filters to focus on the information that is important to you, then bookmark this page to make it a regular stop anytime you’re online.


A New Job for Xalkori
The US Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat patients with advanced non-small cell lung cancer (NSCLC) who have tumors with an ROS-1 gene alteration.
Lung Cancer Rx Reduced Kidney Function
In 2011, the US Food and Drug Administration fast-tracked the approval of Xalkori (crizotinib) to treat a specific type of non-small cell lung cancer (NSCLC). Since its approval, side effects have been discovered.
Targeting Lung Cancer Bad Actor
In the cancer world, a protein called Hsp90 is a bad actor. It helps a number of different cancers survive and thrive. An experimental medication may become Hsp90’s worst nightmare.
New Gene Test IDs Patients for Cancer Drug
Targeted therapy can do wonders. The trick is finding which patients have the genetic mutation or some other alteration that drugs can effectively target.
Targeted Cancer Therapy Casts Wider Net
Targeting cancer gene mutations has been changing the way non-small cell lung cancer ( NSCLC ) is treated. As scientists learn more about the genetic makeup of tumors, more personalized therapy has become available.
An Alternative When Cancer Grows
When non-small cell lung cancer ( NSCLC ) grows again after shrinking on targeted therapy, patients may turn to chemotherapy. Adding local therapy to targeted drugs could offer another solution.
Pfizer Drug Receives Positive Opinion for Lung Cancer
Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU).
Pfizer Announces Positive Results From Xalkori Trial
Pfizer Inc. announced today that the PROFILE 1007 study demonstrated that XALKORI ( crizotinib ) significantly improved progression-free survival ( PFS ) when compared with pemetrexed or docetaxel , in previously treated patients with anaplastic lymphoma kinase ( ALK )-positive advanced non-small cell lung cancer ( NSCLC ).
FDA Approves Xalkori and Vysis ALK Break Apart FISH Probe Kit
The U.S. Food and Drug Administration today approved Xalkori ( crizotinib ) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers ( NSCLC ) who express the abnormal anaplastic lymphoma kinase ( ALK ) gene.